Ramelteon : A Melatonin Receptor Agonist for the Treatment of Insomnia

摘要

The management of insomnia involves use of nonpharmacological and appropriate pharmacological treatment (1). Benzodiazepine receptor agonists are most commonly prescribed agents for insomnia. But they are associated with a cognitive impairment, along with potential for abuse and dependence (2). The treatment with ramelteon, a novel MT1 and MT2 (melatonin receptor) selective agonist does not appear to impair cognition or motor performance. Data from clinical studies suggest that ramelteon is not likely to cause abuse, physical dependence or withdrawal effects (3).